AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 200 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $320,166 | -12.6% | 12,936 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $366,348 | +4.5% | 12,936 | -15.3% | 0.00% | 0.0% |
| Q1 2023 | $350,614 | -0.2% | 15,264 | +22.1% | 0.00% | 0.0% |
| Q4 2022 | $351,168 | -31.4% | 12,506 | -30.9% | 0.00% | -50.0% |
| Q3 2022 | $512,000 | -93.9% | 18,108 | -95.2% | 0.00% | -91.3% |
| Q2 2022 | $8,362,000 | +167140.0% | 377,160 | +269300.0% | 0.02% | – |
| Q4 2021 | $5,000 | -99.5% | 140 | -99.3% | 0.00% | -100.0% |
| Q3 2021 | $949,000 | -15.6% | 20,572 | +0.8% | 0.00% | 0.0% |
| Q2 2021 | $1,125,000 | +112400.0% | 20,416 | +255100.0% | 0.00% | – |
| Q3 2018 | $1,000 | -100.0% | 8 | -100.0% | 0.00% | -100.0% |
| Q2 2018 | $3,941,000 | -30.3% | 46,794 | -32.3% | 0.01% | -25.0% |
| Q1 2018 | $5,656,000 | +987.7% | 69,160 | +660.6% | 0.02% | +1500.0% |
| Q4 2017 | $520,000 | -72.1% | 9,093 | -67.4% | 0.00% | -80.0% |
| Q3 2017 | $1,861,000 | +61.4% | 27,876 | +24.3% | 0.01% | +66.7% |
| Q2 2017 | $1,153,000 | +171.3% | 22,421 | +207.6% | 0.00% | +200.0% |
| Q1 2017 | $425,000 | +35.4% | 7,290 | -3.0% | 0.00% | 0.0% |
| Q4 2016 | $314,000 | -52.5% | 7,519 | -39.9% | 0.00% | -50.0% |
| Q3 2016 | $661,000 | +222.4% | 12,505 | +156.1% | 0.00% | +100.0% |
| Q2 2016 | $205,000 | +5025.0% | 4,882 | +5093.6% | 0.00% | – |
| Q1 2016 | $4,000 | -99.8% | 94 | -99.6% | 0.00% | -100.0% |
| Q3 2015 | $1,828,000 | -91.0% | 25,900 | -85.8% | 0.01% | -90.2% |
| Q2 2015 | $20,339,000 | +23.2% | 183,000 | +4.6% | 0.06% | +22.0% |
| Q1 2015 | $16,503,000 | -23.2% | 175,000 | -8.7% | 0.05% | -24.2% |
| Q4 2014 | $21,478,000 | +127.3% | 191,700 | +24.5% | 0.07% | +120.0% |
| Q3 2014 | $9,448,000 | +19.4% | 154,000 | -10.8% | 0.03% | +20.0% |
| Q2 2014 | $7,913,000 | -12.0% | 172,700 | -24.8% | 0.02% | -16.7% |
| Q1 2014 | $8,987,000 | +27.9% | 229,550 | -21.7% | 0.03% | +25.0% |
| Q4 2013 | $7,024,000 | -7.0% | 293,300 | +8.6% | 0.02% | -17.2% |
| Q3 2013 | $7,549,000 | – | 270,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |